Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Liabilities and Shareholders Equity (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 4 years of Liabilities and Shareholders Equity data on record, last reported at $1.4 billion in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity changed N/A year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $1.4 billion, up 7.6%, while the annual FY2024 figure was $1.3 billion, 25.14% down from the prior year.
  • Liabilities and Shareholders Equity reached $1.4 billion in Q3 2025 per INDV's latest filing, up from $1.3 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.8 billion in Q4 2021 and bottomed at $1.3 billion in Q4 2024.
  • Average Liabilities and Shareholders Equity over 4 years is $1.6 billion, with a median of $1.6 billion recorded in 2023.
  • The widest YoY moves for Liabilities and Shareholders Equity: up 25.14% in 2024, down 25.14% in 2024.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $1.8 billion in 2021, then fell by 4.04% to $1.8 billion in 2023, then dropped by 25.14% to $1.3 billion in 2024, then rose by 7.6% to $1.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $1.4 billion in Q3 2025, $1.3 billion in Q4 2024, and $1.8 billion in Q4 2023.